WuXi AppTec (2359.HK) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $75.77B | Exchange | HKSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | CN | CEO | Ge Li |
| IPO Date | 2018-12-13 | CAGR | 24.34% |
| Employees | 33,834 | Website | www.wuxiapptec.com |
| Div. Yield | 0.62% | Payout Ratio | 10% |
| Buy Back Yield | 0.4% | Total Yield | 1.02% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $56.48B | P/E | 23.64 | Forward P/E | 23.02 | PEG | — |
| P/S | 14.32 | P/B | 10.82 | P/CF | 45.33 | P/FCF | 56.82 |
| Sales | $7.93B | Sales 1Y | 24.93% | Sales 3Y | 32.12% | Sales 5Y | 169.49% |
| EPS | $1.11 | EPS 1Y | 55.44% | EPS 3Y | 137.38% | EPS 5Y | 450.37% |
| Sales QoQ | 31.81% | EPS QoQ | 37.97% | Sales QoQ Avg | 10.8% | EPS QoQ Avg | 18.36% |
| Gross Margin | 51.96% | Operating Margin | 42.43% | Profit Margin | 40.47% | ROCE | 25.86% |
| ROA | 19% | ROE | 27% | Altman Z Score | 10.17 | Piotroski Score | 5 |
| Current Ratio | 2.54 | Quick Ratio | 2.15 | Cash Ratio | 0.94 | Op. CF Ratio | 0.12 |
| Debt/Equity | 0.18 | Debt/Assets | 0.13 | Lt Debt/Equity | 0.03 | Lt Debt/Cap. | 0.02 |
| Intrst Cov. | 107.25 | Inventory Turnover | 2.31 | Asset Turnover | 0.46 | Receivables Turnover | 4.12 |
| Enterprise Value | $56.48B | P/E Ratio | 23.64 |
| Forward P/E | 23.02 | PEG Ratio | — |
| P/S Ratio | 14.32 | P/B Ratio | 10.82 |
| P/CF Ratio | 45.33 | P/FCF Ratio | 56.82 |
| EPS | $1.11 | EPS Growth 1Y | 55.44% |
| EPS Growth 3Y | 137.38% | EPS Growth 5Y | 450.37% |
| Revenue Growth 1Y | 24.93% | Gross Margin | 0.52% |
| Operating Margin | 0.42% | Profit Margin | 0.4% |
| ROE | 0.27% | ROA | 0.19% |
| ROCE | 0.26% | Current Ratio | 2.54 |
| Quick Ratio | 2.15 | Cash Ratio | 0.94 |
| Debt/Equity | 0.18 | Interest Coverage | 107.25 |
| Altman Z Score | 10.17 | Piotroski Score | 5 |
WuXi AppTec (2359.HK) valuation & financials
WuXi AppTec (2359.HK) has a market capitalization of 75.77B HKD and trades at a price-to-earnings ratio of 23.6. It operates in the Healthcare sector (Medical - Diagnostics & Research).
WuXi AppTec's revenue grew +24.9% over the last year.
WuXi AppTec's next earnings report is scheduled for October 28, 2026; analysts estimate EPS of 0.26 HKD. Check the earnings calendar to see all companies reporting this week.
WuXi AppTec (2359.HK) — frequently asked questions
When does WuXi AppTec (2359.HK) report earnings next?
WuXi AppTec is expected to report earnings on October 28, 2026. Analysts estimate EPS of 0.26 HKD.
What is WuXi AppTec's market cap?
WuXi AppTec (2359.HK) has a market capitalization of 75.77B HKD.
What is 2359.HK's P/E ratio?
WuXi AppTec trades at a price-to-earnings ratio of 23.6, with trailing twelve-month EPS of 1.11 HKD.
How fast is WuXi AppTec growing?
WuXi AppTec's revenue grew +24.9% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)